Highlights and external features of Health Evidence Digest.
| Hemostasis Today — Featured Post (September 2026) Health Evidence Digest was selected by Hemostasis Today for their weekly roundup highlighting notable hematology posts. Our analysis of Imaavy (nipocalimab) FDA approval was selected by Hemostasis Today for their weekly roundup, “10 Posts Not to Miss This Week.” They highlighted our clinical breakdown of: – Warm autoimmune hemolytic anemia – FcRn blockade mechanism – ENERGY trial outcomes – Selective IgG reduction and clinical relevance Read the feature: https://hemostasistoday.com/blog/10-posts-80305 |
| Hemostasis Today — Author Insight Feature (July 2026) Hemostasis Today published a dedicated Insight feature spotlighting our clinical analysis of Wilate’s expanded FDA approval. Hemostasis Today published a dedicated feature highlighting our clinical analysis of Wilate’s expanded FDA approval for prophylaxis in children under 6 with von Willebrand disease. The Insight article summarizes key points from our evidence review, including: – VWD as the most common inherited bleeding disorder – Lack of FDA‑approved prophylaxis options for young children until 2026 – Phase 3 WIL‑33 trial outcomes (ABR, bleed severity, infusion requirements) – Clinical significance of age‑inclusive VWF prophylaxis Read the feature: https://hemostasistoday.com/insight/melina-rodriguez-70989 |